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Objectives The objective was to define the characteristics of a real-world patient population treated with transcatheter aor-
tic valve implantation (TAVI), regardless of technology or access route, and to evaluate their clinical outcome
over the mid to long term.
Background Although a substantial body of data exists in relation to early clinical outcomes after TAVI, there are few data on
outcomes beyond 1 year in any notable number of patients.
Methods The U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry was established to report out-
comes of all TAVI procedures performed within the United Kingdom. Data were collected prospectively on 870
patients undergoing 877 TAVI procedures up until December 31, 2009. Mortality tracking was achieved in 100%
of patients with mortality status reported as of December 2010.
Results Survival at 30 days was 92.9%, and it was 78.6% and 73.7% at 1 year and 2 years, respectively. There was a
marked attrition in survival between 30 days and 1 year. In a univariate model, survival was significantly ad-
versely affected by renal dysfunction, the presence of coronary artery disease, and a nontransfemoral approach;
whereas left ventricular function (ejection fraction 30%), the presence of moderate/severe aortic regurgitation,
and chronic obstructive pulmonary disease remained the only independent predictors of mortality in the multi-
variate model.
Conclusions Midterm to long-term survival after TAVI was encouraging in this high-risk patient population, although a sub-
stantial proportion of patients died within the first year. (J Am Coll Cardiol 2011;58:2130–8) © 2011 by the
American College of Cardiology Foundation
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(1,2). Surgical aortic valve replacement (AVR) has, until
recently, been the only effective treatment in adults with
severe symptomatic aortic stenosis. For patients who are
selected for isolated surgical aortic valve replacement the
overall perioperative risk is low (3,4). However, the opera-
tive risk is increased for elderly patients, for patients with
concomitant coronary artery disease or severely reduced left
ventricular (LV) function and also for patients with comor-
bid conditions such as cerebral and peripheral vascular
disease, renal failure, and respiratory dysfunction (3,4).
See page 2139
Transcatheter aortic valve implantation (TAVI) was de-
veloped as an alternative to AVR in this high-risk patient
population. The first implant in man was performed by
Cribier (5) in 2002, using a balloon expandable frame and
equine valve. Currently, 2 devices are under post-marketing
surveillance in Europe: the balloon-expandable Edwards
SAPIEN prosthesis (Edwards Lifesciences, Irvine, Califor-
nia) and the self-expandable CoreValve revalving prosthesis
(Medtronic, Minneapolis, Minnesota). A substantial body
of data now exists in relation to the early clinical outcomes
after TAVI but there are few data on outcome beyond 1 year
in any notable number of patients. A number of observa-
tional clinical studies demonstrated the feasibility (6,7) of
TAVI leading its use as an alternative treatment in these
patients (8–10). There are a number of reports that have
emanated from post-marketing device specific and national
registries (11–17). In general, these have been limited to
selected centers, largely focused on 1 or another technology
and usually have been dependent of industry funding. To
date, none of these registries has reported significant num-
bers of patients with long-term follow-up.
Cohort B of the PARTNER (Placement of Aortic
Transcatheter Valve) trial compared the outcome after
TAVI compared with medical therapy in a very high risk
patient population considered unsuitable for surgery (18).
One-year survival and cardiac symptoms were significantly
and markedly better in the TAVI arm, with only 5
patients needing to be treated to prevent 1 death at 12
months. There was, however, a higher incidence of stroke
and major vascular complications. Cohort A of the
PARTNER trial compared TAVI to AVR in a high-risk
population in whom both therapies were considered
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accepted August 9 2011.clinically acceptable (19). This
study showed noninferiority of
TAVI to AVR for the primary
endpoint of all cause 1-year
mortality but an increased risk of
stroke at 30 days and 1 year in
the TAVI arm. This trial took
place in tightly defined and
highly selected patients in highly
selected centers with a single
technology (Edwards SAPIEN).
In 2007, as the first patients in
the United Kingdom were being
considered for TAVI, a national
program was established to coor-
dinate and monitor the practice
and dissemination of TAVI. The
purpose of this project was to
define the characteristics and
clinical outcomes of the patient population treated with
TAVI (regardless of technology or access route) in every
(i.e., nonselected) center undertaking TAVI. In this paper,
we report the outcomes (survival status as of December 12,
2010) of all TAVI procedures undertaken in England and
Wales between the first implant in January 2007 until the
end of December 2009.
Methods
A total of 25 centers throughout England and Wales
developed active TAVI programs between January 2007 and
December 2009. All centers underwent structured training,
comprising didactic sessions, simulator training, and visits
to experienced centers to observe cases. Proctors attended
cases at the new institution until the institution, proctors,
and the manufacturing company were confident that suffi-
cient expertise had been acquired to permit safe and
independent implantation. The following technologies were
available to these units: the Medtronic CoreValve system
(approved for commercial use in the European Union in
May 2007) and the Edwards SAPIEN valve (the transfemo-
ral delivery system approved in November 2007 and
transapical in January 2008).
All potential patients went through a systematic process
of clinical evaluation, angiographic and echocardiographic
assessment. Patient selection was effected in each individual
unit through a multidisciplinary team process. These teams
consisted not only of cardiac surgeons and interventional
cardiologists but also of many other medical specialties and
allied professionals. Most centers used devices from only 1
manufacturer. The decision as to the access route to be used
was determined by the multidisciplinary team. All centers
adopted a “transfemoral first” selection policy with criteria
for a nontransfemoral approach based upon the multidisci-
plinary team’s consideration of the size and also the degree
Abbreviations
and Acronyms
AR  aortic regurgitation
AVR  aortic valve
replacement
CAD  coronary artery
disease
CCAD  Central Cardiac
Audit Database
COPD  chronic
obstructive pulmonary
disease
LV  left ventricular
NYHA  New York Heart
Association
TAVI  transcatheter aortic
valve implantationof tortuosity, calcification, and atheroma of the aortoilio-
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the transfemoral or transapical routes, and the CoreValve by
transfemoral, subclavian, or occasionally direct aortic access.
There was a small volume of cross-referral between centers,
of patients who were deemed to be more suitable for 1
particular device, when this was not available at the original
center.
In 2007, the Society for Cardiothoracic Surgery in Great
Britain and Ireland and the British Cardiovascular Inter-
vention Society agreed a dataset of demographics, risk
factors, and outcome measures to be collected on all
patients. The Central Cardiac Audit Database (CCAD)
(20) established a web-based system for data entry, encryp-
tion, and transfer (the dataset and definitions are provided
in Online Table 1). A total of 25 centers throughout
England and Wales developed TAVI programs between
January 2007 and December 2009 (see Online Appendix for
contributing hospitals). All 25 units have submitted their
data to CCAD on all patients treated, retrospectively for
patients treated before establishing the database and pro-
spectively thereafter. To the end of December 2009, data
from all cases treated in England and Wales were entered
into the database. No patient having a TAVI was excluded
from analysis.
Mortality tracking was undertaken by the National
Health Service Central Register by using unique patient
identifiers. It is a legal requirement for all deaths in the
United Kingdom to be registered with this body. It is not
possible to effect any form of burial/cremation or similar
process for the deceased without such registration. Thus,
tracking yields very robust results. Survival status for the
whole cohort of patients was determined through the NHS
Central Register as of December 12, 2010.
Periprocedural and post-procedural complications were
self-reported according to definitions defined within the
national dataset (Supplementary Table 1) with post-
implantation aortic regurgitation (AR) assessed visually
according to standard angiographic criteria at the termina-
tion of the implantation procedure.
All of these processes were performed in compliance with
current U.K. Data Protection and Information Governance
legislation. All patients provided signed, informed consent.
Data cleaning. All fields were examined for missing data
or extreme values, and contributing units were asked to
complete or correct data where possible. Extreme data were
verified and excluded only if found to be erroneous.
Statistics. Categorical data were presented as percentages,
and comparison between groups done by the chi-square test
or the Fisher’s exact test. Numerical data were presented as
mean  SD or median (interquartile range), and compari-
sons done with the 2-sample t test or the 2-sample Wil-
coxon rank-sum (Mann-Whitney) test. Time-to-event data
analysis was done using the Cox proportional hazards
model. The Kaplan-Meier survival curves were drawn to
assess differences between groups for the time to an event
data. For the Cox model, univariate analysis of each ofthe possible predictors of the outcome were tested. Those
variables that were significant at p  0.05, and the
presence of peripheral vascular disease were included in a
multivariate model to determine the independent predic-
tors of the outcome variables. The analysis was done
using Stata version 10.1 statistical software (StataCorp,
College Station, Texas).
Results
Demographic and baseline characteristics. Completeness
of valid data was 99.6% for demographic data, 96.4% for
risk factors, 97.4% for procedural variables, and 98.5% for in
hospital outcomes. Eighteen of the 25 units had valid data
completeness of 98%. Mortality tracking was achieved in
100% of patients with survival status reported as of Decem-
ber 12, 2010. Follow-up ranged from 11 months to 46
months.
Data from 877 implants in 870 patients were submitted
to the CCAD. In 7 patients, a subsequent TAVI was
performed as a vale-in-valve procedure at a later date to the
original implant. In the analysis of survival, the second
procedure was censored.
The Registry thus contains the records of 870 patients.
The number of implants per year increased from 66 in 2007,
to 273 in 2008, and to 538 in 2009. The median number of
implants per center was 24 (range 5 to 114). Baseline
demographics and risk factors are shown in Table 1.
Significant concomitant coronary artery disease (CAD [de-
fined as 50% stenosis affecting 1 major epicardial
coronary artery]) was present in 410 patients (48%).
The majority (69%) of implants were by the transfemoral
route. More than one-half of the SAPIEN implants were
transapical, in contrast to almost 90% of CoreValve im-
plants being through the transfemoral route (Table 1). The
presence of peripheral vascular disease, CAD, prior cardiac
surgery, renal dysfunction, and New York Heart Associa-
tion (NYHA) functional class III or IV symptoms were
significantly more common in patients having TAVI by a
nonfemoral approach compared with a transfemoral ap-
proach (Table 1). The median logistic European System for
Cardiac Operative Risk Evaluation (EuroSCORE) was
18.5%, and was lower in the transfemoral cohort (17.1%)
than in the nontransfemoral cohort (21.4%; p  0.0001).
There were similar numbers of CoreValve and SAPIEN
implants (459 vs. 410; unknown in 8); and 41% of all
CoreValve and 28% of all SAPIEN implants were proc-
tored. Patients treated with the SAPIEN valve tended to be
older and were more likely to be in NYHA functional class
III/IV and to have a greater likelihood of having coronary
and peripheral vascular disease (Table 1) than were Core-
Valve treated patients.
Procedural parameters and outcomes. Periprocedural
parameters and outcomes are defined in Table 2. Proce-
dural success was achieved in 846 patients (97.2%).
Implantation was unsuccessful in 8 cases, and emergency
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of whom had a SAPIEN implant via a transapical approach
(2.2% of transapical implants) (Table 2).
Post-procedural (30-day) complications. The incidence
of major complications is described in Table 2. The inci-
dence of stroke and myocardial infarction was 4.1% and
1.3%, respectively. The requirement for a new permanent
pacemaker was significantly more common with CoreValve
implants than with SAPIEN (24.4% vs. 7.4%; p  0.0001).
ome degree of paravalvar AR (angiographic grade 1)
ccurred in 61% of patients, with this being moderate to
evere (AR 2) in 13.6%. Moderate to severe leaks were
ignificantly more common with the CoreValve device.
ajor vascular complications were reported in 6.3% of
atients, and occurred predominantly in the transfemoral
ohort (8.4%).
DemographicsTable 1 Demographics
Variables
All Patients
(n  870)
Transfemoral Route
(n  599)
O
Male 456/870 (52.4) 311/599 (51.9) 14
Age, yrs 81.9 7.1 81.7 7.4 8
AV peak gradient 80.9 27.2 82.1 27.8 7
LVEF 50% 553/865 (64.0) 382/597 (64.0) 17
LVEF 30%–49% 238/865 (27.0) 166/597 (28.0) 7
LVEF 30% 74/865 (9.0) 49/597 (8.0) 2
NYHA functional class I/II 199/866 (23.0) 156/597 (26.1) 4
NYHA functional class III/IV 667/866 (77.0) 441/597 (73.9) 22
Coronary disease 394/828 (47.6) 249/574 (43.4) 14
Any previous cardiac
surgery
259/853 (30.4) 160/586 (27.3) 9
PVD 241/832 (29.0) 110/563 (19.5) 13
Diabetes mellitus 196/861 (22.8) 137/595 (23.0) 5
COPD 239/834 (28.7) 158/574 (27.5) 8
Creatinine 200 mmol/l 55/863 (6.7) 32/588 (5.4) 2
Logistic EuroSCORE 18.5 (11.7–27.9) 17.1 (11.0–25.5) 21.
Values are n/N (%), mean  SD, or median (interquartile range).
AV  aortic valve; COPD  chronic obstructive pulmonary disease; EuroSCORE  European Sy
ascular disease.
OutcomesTable 2 Outcomes
Variables
All Patients
(n  870)
Transfemoral Route
(n  599)
Procedural success 846/870 (97.2) 583/599 (97.3)
All-cause mortality at end of follow-up 249/870 (28.6) 153/599 (25.5)
30-day survival, % dead 62/870 (7.1) 33/599 (5.5)
1-yr survival, % dead 186/870 (21.4) 111/599 (18.5)
2-yr survival, % dead 229/870 (26.3) 135/599 (22.5)
MACCE, in hospital 90/870 (10.3) 56/599 (9.4)
Stroke, in hospital 35/864 (4.1) 24/594 (4.0)
MI 11/864 (1.3) 6/594 (1.0)
AR moderate/severe 115/849 (13.6) 91/585 (15.6)
Surgical conversion 6/850 (0.7) 0/592 (0)
Major vascular complication 55/869 (6.3) 50/598 (8.4)
Repeat procedure 7/870 (0.8) 7/599 (1.2)
Pacemaker 141/867 (16.3)Values are n/N (%). *Fisher exact test.
AR  aortic regurgitation; MACCE  major adverse cardiovascular and cerebrovascular events; MI  marly survival. Survival for the whole cohort at 30 days was
2.9%. There was a higher 30-day mortality among patients
eceiving a nontransfemoral implant compared with patients
eceiving a transfemoral TAVI (p  0.03) (Table 2). There
ere some significant demographic differences between
hese cohorts (Table 2).
idterm and long-term survival. The Kaplan-Meier sur-
ival curve for the whole population is shown in Figure 1.
urvival at 1 year and 2 years was 78.6% and 73.7% at 1 and
years, respectively (with 651 and 213 patients alive and at
isk at 1 and 2 years follow-up, respectively). There was a
arked attrition in survival between 30 days and 6 months,
ith 9.6% of patients dying during this period and a further
.7% between 6 months and 1 year. There was no difference
n survival at 1 year between patients in the SAPIEN cohort
ompared with the CoreValve cohort. There was a signifi-
outes
71) p Value
Medtronic CoreValve
(n  452)
Edwards SAPIEN
(n  410) p Value
(53.5) 0.66 235/452 (52.0) 217/410 (52.9) 0.78
6.6 0.32 81.3 7.4 82.6 6.7 0.007
25.7 0.05 83.4 28.5 77.5 25.0 0.003
(63.8) 288/452 (63.7) 262/406 (64.5)
(26.9) 0.85 123/452 (27.2) 112/406 (27.6) 0.82
(9.3) 41/452 (9.1) 32/406 (7.9)
(16.0) 0.001 118/452 (26.1) 80/406 (19.7) 0.03
(84.0) 334/452 (73.9) 326/406 (80.3)
(57.1) 0.001 194/436 (44.5) 198/384 (51.6) 0.04
(37.1) 0.004 129/439 (29.4) 126/406 (31.0) 0.60
(48.7) 0.001 109/423 (25.8) 130/401 (32.4) 0.04
(22.2) 0.79 101/450 (22.4) 92/403 (22.8) 0.89
(31.2) 0.28 120/438 (27.4) 115/388 (29.6) 0.48
(9.4) 0.03 28/444 (6.3) 28/401 (7.0) 0.69
4–33.6) 0.001 18.1 (11.1–27.9) 18.5 (12.4–27.7) 0.34
or Cardiac Operative Risk Evaluation; LVEF  left ventricular ejection fraction; PVD  peripheral
er Routes
n  271) p Value
Medtronic CoreValve
(n  452)
Edwards
(n  410) p Value
/271 (97.1) 0.82 444/452 (98.2) 402/410 (98.1) 0.84
/271 (35.4) 0.003 122/452 (27.0) 122/410 (29.8) 0.37
/271 (10.7) 0.006 26/452 (5.8) 35/410 (8.5) 0.11
/271 (27.7) 0.002 93/452 (21.7) 89/410 (20.6) 0.68
/271 (36.7) 0.001 108/452 (23.9) 116/410 (28.3) 0.14
/271 (12.6) 0.15 42/452 (9.3) 48/410 (11.7) 0.25
/270 (4.1) 0.98 18/448 (4.0) 17/408 (4.2) 0.91
/270 (1.9) 0.31 5/447 (1.1) 6/409 (1.5) 0.65
/264 (9.1) 0.01 76/439 (17.3) 39/405 (9.6) 0.001
/268 (2.2) 0.001* 0/450 (0) 6/402 (1.5) 0.01*
/271 (1.9) 0.001 28/451 (6.2) 26/410 (6.3) 0.94
/271 (0) 0.11* 7/452 (1.6) 0/410 (0) 0.02*
110/451 (24.4) 30/408 (7.4) 0.001ther R
(n  2
5/271
2.3
7.9
1/268
2/268
5/268
3/269
6/269
5/254
9/267
1/269
9/266
1/260
5/265
4 (14.Oth
(
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0yocardial infarction.
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nontransfemoral route of implantation (Fig. 2). Actual
1-year mortality was 18.5% with transfemoral and 22.7%
with nontransfemoral. This difference persisted at 2
years, with a mortality of 22.5% in the transfemoral
cohort compared with 36.7% in the nontransfemoral
cohort (Table 2).
The predictors of mortality (at 1 year post-implant)
within the univariate and multivariate analyses are shown in
Table 3. In the univariate model, survival was significantly
adversely affected by LV dysfunction, renal dysfunction, the
presence of concomitant coronary artery disease or chronic
obstructive pulmonary disease (COPD), the presence of
moderate or severe AR, and a nontransfemoral approach.
Age, NYHA functional class, or type of device implanted
did not affect survival. Left ventricular function (ejection
fraction 30%), the presence of COPD, and the presence
of moderate or severe AR (Table 3) were the only indepen-
dent predictors of mortality in the multivariate model. As
noted in the preceding text, the early survival advantage in
the patients treated with CoreValve implants was no longer
apparent at 1 year.
There was no difference in survival at 1 year between
cohorts of patients with a logistic EuroSCORE of 0 to 20
and 21 to 40, but a marked and significant reduction in
midterm survival for patients with a logistic EuroSCORE
of40 (Fig. 3). There was no difference in survival between
proctored and nonproctored cases, or between the first 20
patients having implants in any individual unit and that in
subsequent patients.
Discussion
This national, multicenter study reports a large consecutive
and all-inclusive series of patients diagnosed with severe
Figure 1 Survival Curves for Whole Cohort of 870 Patients
Event rate was calculated by the Kaplan-Meier method. Shaded area indicates
95% confidence interval (CI); darker line indicates survivor function.symptomatic aortic stenosis who underwent TAVI. Theywere all deemed to be at high risk for conventional surgery,
on the basis of the clinical judgment of the multidisciplinary
team within each individual unit. The U.K. TAVI Registry
is unique in that it has captured every TAVI performed at
all the 25 active units within England and Wales, and thus
includes the entire “learning curve” and early experience of
adopting centers without any publication bias that might be
induced by center selection. The data reported here provide
the first results from the U.K. Registry and encompasses a
substantial number of implants with both the Medtronic
CoreValve and the Edwards SAPIEN valve. All previously
reported TAVI registries are device specific or from selected
centers. These data from the U.K. Registry reflect the
largest series of consecutive cases reported to date of
midterm and long-term outcomes after TAVI with 200
patients alive and at risk 2 years post-implant. The mini-
mum follow-up was 11 months.
Principle findings. In this cohort of patients the 30-day
mortality was 7.1%. The rate observed in this registry was
similar to that reported in previous registries: Canadian
registry, 10.4% (12); SOURCE (SAPIEN Aortic Biopros-
thesis European Outcome) registry, 8.5% (15); FRANCE
(French Aortic National CoreValve and Edwards) registry,
12.7% (11); German registry, 8.2% (16); and Italian registry,
5.4% (13). In the PARTNER B cohort, 30-day mortality
was 5%, and it was 5.2% in the PARTNER A cohort (as
treated analysis) (18,19). This (7.1%) mortality allied to a
significant reduction in 30-day mortality that occurred with
time (30-day mortality for the 2009 cohort was 4.3%) is an
encouraging statistic in relation to the further dissemination
of TAVI.
The majority (85%) of nontransfemoral approach cases
were effected by a transapical approach. The higher mortal-
ity in the nontransfemoral cohort, compared with the
Figure 2 Survival Curves by Access Route
Survival curves for transfemoral access route (orange broken line) and non-
transfemoral route (green solid line). Event rates calculated by the Kaplan-
Meier method and compared with the use of the log-rank test.
2135JACC Vol. 58, No. 20, 2011 Moat et al.
November 8, 2011:2130–8 The U.K. TAVI Registry Long-Term Outcomesfemoral cohort, is comparable to that seen in almost all
studies (15,18). Although a nontransfemoral approach con-
ferred a significantly increased risk of death at 30 days and
at 1 year and 2 years of follow-up and was a predictor of an
adverse outcome in the univariate analysis, it was not an
independent predictor of mortality at 1 year. The explana-
tion is probably multifactorial. It is clear that the nontrans-
femoral cohort of patients has a more adverse risk profile
Predictors of Mortality at 1 YearTable 3 Predictors of Mortality at 1 Year
Variables Alive (n  684) Dead (n  186)
Edwards SAPIEN 321/680 (47.2) 89/182 (48.9)
Medtronic CoreValve 359/680 (52.8) 93/182 (51.1)
Route, other 196/684 (28.7) 75/186 (40.3)
Route, transfemoral 488/684 (71.3) 111/186 (59.7)
AR moderate/severe 83/674 (12.3) 32/175 (18.3)
Major vascular complication 39/684 (5.7) 16/185 (8.7)
Permanent pacemaker 108/683 (15.8) 33/184 (17.9)
Male 355/684 (59.9) 101/186 (54.3)
Age, yrs 81.8 7.3 82.3 6.4
AV gradient 81.1 27.1 79.9 27.8
LVEF 50% 459/680 (67.5) 94/185 (50.8)
LVEF 30%–49% 169/680 (24.9) 69/185 (37.3)
LVEF 30% 52/680 (7.6) 22/185 (11.9)
NYHA functional class I/II 160/680 (23.5) 39/186 (21.0)
NYHA functional class III/IV 520/680 (76.5) 147/186 (79.0)
Coronary disease 301/653 (46.1) 93/175 (53.1)
Any previous cardiac surgery 202/667 (30.3) 57/186 (30.7)
PVD 179/654 (27.4) 62/178 (34.8)
Diabetes mellitus 146/675 (21.6) 50/136 (26.9)
COPD 176/654 (26.9) 63/180 (35.0)
Creatinine 200 mmol/l 38/668 (5.7) 19/185 (10.3)
Values are n/N (%), mean  SD, or hazard ratio (95% confidence interval).
CI  confidence interval; HR  hazard ratio; other abbreviations as in Tables 1 and 2.
Figure 3 Survival Curves by Log EuroSCORE
Survival curves by logistic European System for Cardiac Operative Risk Evalua-
tion (EuroSCORE [Log Euroscore]): green solid line  0 to 20; orange broken
line  20 to 40; blue broken line  40. Event rates calculated by the
Kaplan-Meier method and compared with the use of the log-rank test.than patients who can be treated by the femoral approach,
but it is also possible that aspects of the transapical proce-
dure per se may confer an increased risk.
We report midterm survival after TAVI in a large cohort
of patients for whom mortality tracking was achieved in
100% of cases. Kaplan-Meier survival was 78.6% and 73.7%
at 1 and 2 years, respectively. The numbers of patients “at
risk” in the Kaplan-Meier analyses were 651 and 213 at 1
year and 2 years, respectively (in comparison to 260 and 67,
respectively, in the PARTNER cohort A (19).
In addition to death occurring within 30 days of proce-
dure, there was a marked ongoing attrition in the first 6
months post-implant (with 9.6% of patients dying between
30 days and 6 months and 4.7% dying between 6 months
and 1 year). This high attrition in the first year post-implant
is also seen in the SOURCE registry and the Italian
registries and in both cohorts of the PARTNER trial; for
example, 18% of patients died after a TAVI between 30
days and 1 year in PARTNER A. It is of interest that there
was an almost identical rate of attrition in the control
(AVR) group. Our data show that this high rate of attrition
decreases substantially after 1 year, with 21.4% of patients
dying within the first year but only 4.9% (of the original
cohort) between 1 and 2 years. This pattern of survival
closely matches that reported in the U.K. Surgical Database
for octogenarians undergoing either AVR or AVR with
concomitant coronary artery bypass grafting, with a high
rate of attrition in the first 6 months followed by an ongoing
constant risk of dying of 5% to 6% per year over the next 3
Univariate Model p Value Multivariate Model p Value
1.00
0.95 (0.70–1.29) 0.75
1.00
0.65 (0.48–0.88) 0.006 0.73 (0.52–1.04) 0.08
1.49 (1.00–2.21) 0.048 1.66 (1.10–2.51) 0.016
1.42 (0.82–2.45) 0.21
1.21(0.83–1.77) 0.32
1.19 (0.88–1.61) 0.25
1.01 (0.99–1.03) 0.52
.996 (0.990–1.002) 0.20
1.00 1.00
1.93 (1.40–2.66) 0.001 1.49 (1.03–2.16) 0.03
1.89 (1.16–3.07) 0.01 1.65 (0.98–2.79) 0.06
1.00
1.14 (0.79–1.63) 0.50
1.38 (1.01–1.87) 0.04 1.23 (0.88–1.73) 0.23
1.04 (0.75–1.43) 0.83
1.28 (0.91–1.75) 0.16
1.36 (0.98–1.89) 0.07
1.40 (1.02–1.93) 0.04 1.41 (1.00–1.98) 0.05
1.84 (1.14–2.97) 0.012 1.55 (0.90–2.68) 0.110years (4).
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between patient cohorts with logistic EuroSCORE of 0 to
20 and 21 to 40 reaffirms the relative lack of utility in this
scoring system in risk/outcome prediction for this group of
patients and confirms the need for more sophisticated and
procedure specific (rather than generic) scoring systems
(21). In the cohort with a logistic EuroSCORE  40, it is
again interesting to note that the 30-day mortality was not
significantly different from the logistic EuroSCORE 0 to 20
and 21 to 40 cohorts but that midterm mortality was
significantly inferior. Almost 25% of the logistic Euro-
SCORE 40 cohort of patients died between 30 days and
6 months. The poor outcome during this 30-day to
6-month period for these very high risk patients warrants
further investigation, in particular to determine whether
patients who are likely not to survive to 6 months or even 1
year can be prospectively identified.
In the univariate analysis, impaired LV ejection fraction,
transfemoral access, CAD, the presence of moderate or
severe AR, COPD, and renal dysfunction had an adverse
impact on survival. However, interestingly, neither age,
NYHA functional class, nor the presence of peripheral
vascular disease were significantly associated with survival.
In the multivariate analysis, the only independent predictors
of survival were an LV ejection fraction30%, the presence
of moderate or severe AR, and COPD.
These data encompass the learning curve of all units with
this technique. The observation that 30-day and midterm
mortality was equivalent in proctored cases and in nonproc-
tored cases, and in the first 20 cases compared with
subsequent cases in each unit, reflects well on the process of
education, training, and mentorship established by both of
the companies with current commercially available devices.
It also suggests good judgment of both the centers and
proctors as to when a unit is able to progress to stand-alone
implantation. Further growth and dissemination of TAVI
should retain this robust training structure in addition to a
strict multidisciplinary approach.
The incidence of early stroke is not surprising, given the
patient population, and is comparable to other registries and
to the PARTNER trial. The finding of magnetic resonance
imaging evidence of (albeit seemingly silent) cerebral per-
fusion defects in 84% of TAVI patients (22) highlights the
need to evaluate neurological outcomes in these patients,
including cognitive function. Embolic protection devices
may have a role in ameliorating the incidence of stroke, but
at present it remains a major concern and represents an
obstacle to the application of TAVI in lower risk patients.
The significantly higher rate of permanent pacemaker
requirement with CoreValve implantation confirms previ-
ous reports (23,24) and is likely due to the presence of the
stent within the subvalvar LV outflow tract with impinge-
ment on the left branch of the Bundle of His. Not
surprisingly, the presence of pre-procedural right bundle
branch block conveys a very high risk of permanent pace-
maker implantation after CoreValve implantation (25).In 61% of patients, there was a degree of paravalvular AR
that would traditionally have been regarded as suboptimal or
even unacceptable after AVR. The finding that the degree
of post-implant AR was an independent predictor of sur-
vival at 1 year is an important observation and requires
further detailed study. Whether the regurgitation is respon-
sible for this adverse outcome or is merely a marker for other
adverse features cannot be assessed from this registry. The
presence of moderate or severe AR was more common in
the Medtronic CoreValve cohort. There is some evidence
that the degree of AR remains stable or even reduces during
the first year post-implant (26). The influence of this
residual AR on parameters such as the incidence of endo-
carditis and hemolysis and the effect on LV mass regression
are unknown and will need to be further evaluated. A
reduction in the incidence and severity of paravalvular AR
represents an obvious target for technical improvements in
the design of transcatheter valves and of implantation
techniques.
The observation that COPD was an independent predic-
tor of outcome is perhaps surprising. In patients with aortic
stenosis and COPD, it can be difficult to be certain as to the
precise contribution of each pathology in an individual
patient with progressive severe breathlessness. For patients
in whom COPD predominates, the relief of aortic stenosis
may not change the clinical outcome as much as in other
patient groups, and that may in part explain this observation.
Comparison of the incidence of major vascular compli-
cations between case series is complicated by differing
definitions. The incidence of major iliofemoral complica-
tions in 1 study (in the same patients) was shown to vary
between 4% and 13% depending upon the definitions used
(27) The data fields collected in the U.K. Registry (see
Appendix) would be expected to capture the major, but not
the less serious, vascular complications. Despite this, the
reported rate of 8.4% among transfemoral patients in our
series is high, though comparable to other reports (27–29)
Further studies are required to identify the risk factors for
and precise nature of these peripheral vascular complica-
tions. It is hoped that improvements in technology and
technique and in the selection of the optimal access route for
implantation will reduce the rate of this complication in the
future.
A substantial proportion of patients being considered for
TAVI have concomitant CAD. In this registry, 410 (47%)
patients had CAD (defined as 50% stenosis affecting 1
major epicardial coronary artery). The optimal management
of CAD in the setting of TAVI is not well defined. Hybrid
percutaneous coronary intervention was undertaken in only
55 patients (14% of those patients with CAD). Thus, in this
registry, patients with concomitant CAD have been pre-
dominantly been managed by TAVI alone, with a low
incidence of early myocardial infarction. The presence of
concomitant CAD was identified as a risk factor in the
univariate analysis but was not an independent predictor of
survival at 1 year. This is an interesting observation given
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surgery in elderly patients who require AVR and coronary
artery bypass graft surgery compared with patients under-
going isolated AVR (4). The optimal management of
concomitant CAD is not well defined and is another area in
relation to this patient population that requires further study.
Strengths and limitations of the study. Like all registries,
ours is only as good and credible as the quality of the data
within it. Data completeness in this registry was good, but
whereas data on the numbers of procedures and survival
outcome are believed to be extremely robust, those concern-
ing morbidity and complications are likely less so. Although
internal consistency checks have been applied, these data are
self-reported and have not been systematically validated or
independently adjudicated.
The definitions used in the dataset are not directly
comparable to those in other published reports. The Society
of Thoracic Surgeons score could not be calculated from the
dataset. The recent publication of the VARC (Valvular
Academic Research Consortium-consensus of event defini-
tion) definitions should go some way to improving the
comparability of data from future studies (30).
Value of the study. The U.K. TAVI program was estab-
lished to capture and report outcomes on TAVI procedures
performed within the United Kingdom. In this, the first
report from this registry, the short-term and midterm
outcomes of the 870 patients undergoing TAVI until the
end of 2009 are reported. It is unique in that it is
comprehensive, has captured data from all consecutive
patients in all of the clinically active units, encompasses a
substantial number of implants with both commercially
available technologies utilizing all of the described access
routes, and has robust (100%) overall mortality tracking. It
is also the first report of outcomes beyond 1 year for a
substantial number of patients (850) and demonstrates en-
couraging midterm outcomes for patients who are still alive I
year after TAVI. These real-world data are complementary to
the data emanating from the PARTNER randomized trials.
Conclusions
To summarize, outcomes after TAVI for this high-risk
patient population of patients with severe aortic stenosis
were encouraging. Although 30-day mortality was accept-
able, there was a significant attrition between 30 days and 12
months, predominantly in the highest risk cohort. The rate
of reduction in survival fell markedly after 1 year. These
data, in conjunction with those from other registries and
from the PARTNER trial, suggest that it would be appro-
priate to compare TAVI with surgical AVR in the setting of
a randomized trial in a less high risk cohort of patients.
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APPENDIX
For a list of hospitals contributing patients to this study and a
supplementary table of the dataset and definitions, please see the
online version of this article.
